Skip to main content
Signal8

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

$BIIBPress releaseJun 17, 2026, 6:59 PM ET

Biogen has agreed to acquire private biotechnology company RayThera for up to $1 billion to expand its immunology pipeline with multiple anti-inflammatory assets. The transaction structure includes an upfront payment and additional clinical and regulatory milestone payments, with the lead candidate expected to enter Phase 1 development in early Q3 2026.

Key figures

Deal Value Usd
1000000000
Phase Of Trial
Phase 1

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.